The Stent Grafts Market size was estimated at USD 960.76 million in 2025 and expected to reach USD 1,040.12 million in 2026, at a CAGR of 8.49% to reach USD 1,700.04 million by 2032.

The stent grafts market is anchored by the global shift toward minimally invasive vascular repair for abdominal aortic aneurysm, thoracic aortic aneurysm, aortic dissection, traumatic aortic injury, and selected peripheral vascular conditions. Endovascular aneurysm repair and thoracic endovascular aortic repair have become central treatment pathways because they can reduce surgical trauma, shorten hospital stays, and expand treatment eligibility for older or higher-risk patients when anatomy is suitable.

Demand is supported by population aging, higher use of CT angiography, improved screening in high-risk groups, and steady innovation in low-profile delivery systems, fenestrated and branched devices, conformable graft materials, and enhanced sealing technologies. The market remains clinically rigorous because product selection depends on anatomy, durability, endoleak risk, access-vessel quality, operator experience, and post-procedure surveillance.

The competitive landscape is being reshaped by the migration from conventional open surgery to image-guided endovascular treatment, particularly in high-volume vascular centers. Physicians are prioritizing devices that improve anatomical fit, reduce migration, support complex aortic branch preservation, and simplify deployment in tortuous vessels.

Regulatory and reimbursement pressure is also transforming commercialization. Evidence expectations are rising under frameworks such as the U.S. FDA pathway and the European Medical Device Regulation, while hospitals are assessing total episode cost, reintervention rates, inventory efficiency, and long-term durability. As a result, companies with strong clinical data, physician training programs, and reliable supply chains are better positioned than firms competing mainly on price.

Artificial intelligence is cumulatively influencing the stent graft value chain by improving imaging interpretation, anatomical measurement, case planning, device sizing, and follow-up surveillance. AI-enabled segmentation of CT angiography can help clinicians quantify neck length, angulation, thrombus burden, iliac access, and aneurysm morphology more consistently, supporting better preoperative planning and reducing workflow variation.

AI is also becoming relevant after implantation. Algorithms can support detection of sac expansion, endoleak suspicion, graft migration, and surveillance adherence patterns when integrated with imaging systems and electronic health records. Adoption will depend on validated performance, explainability, cybersecurity, integration with hospital workflows, and clinician oversight, as AI remains a decision-support tool rather than a substitute for vascular expertise.

Asia-Pacific is one of the most dynamic regions for stent grafts as Japan, China, Australia, India, and South Korea expand endovascular capabilities and invest in advanced imaging. Japan benefits from an older population and established vascular care, while China and India offer large patient pools with increasing diagnosis rates and hospital infrastructure expansion. Reimbursement variability and specialist availability continue to influence adoption across emerging markets.

North America remains a leading region due to high procedural maturity, extensive imaging access, strong clinical trial activity, and broad use of EVAR and TEVAR in the United States and Canada. Europe maintains deep clinical expertise across Germany, France, Italy, Spain, and the United Kingdom, although MDR compliance has increased evidence and documentation requirements. Latin America is led by Brazil and Mexico, where private hospitals adopt advanced devices faster than many public systems. The Middle East, especially GCC markets, is supported by specialty hospitals and health investment, while Africa faces slower adoption due to infrastructure, affordability, and trained workforce constraints.

ASEAN presents a mixed access environment for stent grafts, with Singapore, Thailand, and Malaysia showing stronger specialist capacity and Indonesia, Vietnam, and the Philippines expanding gradually as imaging and vascular programs scale. Procurement decisions often balance clinical performance with affordability, service support, and physician training.

The GCC benefits from high healthcare spending, tertiary hospital investment, and demand for advanced cardiovascular care, making it attractive for premium stent graft systems. The European Union remains evidence-driven and quality-focused under MDR, favoring suppliers with robust post-market surveillance and registry data. BRICS countries combine large demand with localization priorities and pricing pressure, while G7 markets shape global standards through clinical evidence, reimbursement scrutiny, and innovation adoption. NATO countries are increasingly attentive to resilient medical supply chains, emergency preparedness, and continuity of critical vascular device access.

The United States is the most influential stent graft market due to procedure volume, FDA-regulated innovation, specialist networks, and reimbursement depth, while Canada emphasizes evidence-based adoption across provincial systems. Mexico and Brazil are important Latin American growth markets, supported by private hospital demand and improving endovascular expertise, although access differs across public and private care settings.

In Europe, the United Kingdom, Germany, France, Italy, and Spain remain major adopters, with Germany benefiting from high hospital capacity and France and the UK emphasizing structured evaluation and reimbursement discipline. Russia maintains demand for aortic repair but faces procurement and supply complexities. China is scaling rapidly through hospital modernization and domestic device development, India is expanding from major metropolitan centers, Japan remains advanced and aging-driven, Australia has strong specialist adoption, and South Korea combines high technology readiness with sophisticated cardiovascular care.

Industry leaders should prioritize clinically differentiated devices that address hostile neck anatomy, iliac access challenges, branch preservation, and long-term durability. Investment in fenestrated, branched, lower-profile, and conformable systems should be paired with rigorous evidence generation, real-world data, and transparent post-market surveillance.

Commercial success will depend on physician education, case-planning support, local reimbursement strategy, and supply reliability. Manufacturers should build AI-ready digital planning ecosystems, partner with imaging and hospital IT providers, and create region-specific portfolios that balance premium innovation with cost-sensitive access. Leaders should also strengthen recall readiness, quality systems, and regulatory documentation to meet expanding global scrutiny.

The research approach combines primary and secondary intelligence to evaluate market direction, technology adoption, regulatory dynamics, and regional demand patterns. Secondary inputs include public health datasets, regulatory databases, clinical guidelines, device approvals, hospital procurement signals, peer-reviewed literature, company filings, and vascular surgery registry information where available.

Primary validation is conducted through structured discussions with vascular surgeons, interventional radiologists, hospital procurement leaders, distributors, payers, and device. Findings are triangulated across clinical practice, commercial activity, reimbursement conditions, and macroeconomic indicators to ensure balanced, data-backed conclusions. AI-related insights are assessed through documented medical imaging use cases, regulatory trends, and practical workflow relevance.

The stent grafts market is positioned for sustained relevance as healthcare systems continue to favor less invasive vascular repair, earlier diagnosis, and outcomes-based device selection. Growth is strongest where aging populations, imaging infrastructure, specialist expertise, and reimbursement support align.

Future leadership will be determined by clinical durability, anatomical versatility, regulatory excellence, digital planning integration, and regional. Companies that combine proven device performance with AI-supported workflows, strong physician partnerships, and resilient supply chains will be best placed to capture demand across mature and emerging stent graft markets.